A Phase 3, Randomized, Open-Label Study Evaluating the Safety and Efficacy of Magrolimab in Combination With Azacitidine Versus Physician's Choice of Venetoclax in Combination With Azacitidine or Intensive Chemotherapy in Previously Untreated Patients With TP53 Mutant Acute Myeloid Leukemia
Latest Information Update: 18 Apr 2024
At a glance
- Drugs Magrolimab (Primary) ; Azacitidine; Azacitidine; Cytarabine; Daunorubicin; Idarubicin; Venetoclax
- Indications Acute myeloid leukaemia
- Focus Registrational; Therapeutic Use
- Acronyms ENHANCE-2
- Sponsors Gilead Sciences
- 11 Apr 2024 This trial has been completed in Germany (End date:2024-02-07) according to European Clinical Trials Database record.
- 24 Feb 2024 This trial has been discontinued in Spain according to European Clinical Trials Database record
- 22 Dec 2023 This trial has been completed in Belgium.